These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19789318)

  • 1. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.
    Drake KM; Ruteshouser EC; Natrajan R; Harbor P; Wegert J; Gessler M; Pritchard-Jones K; Grundy P; Dome J; Huff V; Jones C; Aldred MA
    Clin Cancer Res; 2009 Oct; 15(19):5985-92. PubMed ID: 19789318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
    Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
    Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
    J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of microRNAs in Wilms' tumors.
    Yu X; Li Z; Chan MT; Wu WK
    Tumour Biol; 2016 Feb; 37(2):1445-50. PubMed ID: 26634744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identical genetic changes in different histologic components of Wilms' tumors.
    Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
    J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells.
    Reeve AE; Sih SA; Raizis AM; Feinberg AP
    Mol Cell Biol; 1989 Apr; 9(4):1799-803. PubMed ID: 2542777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms' tumor and gonadal dysgenesis in a child with the 2q37.1 deletion syndrome.
    Viot-Szoboszlai G; Amiel J; Doz F; Prieur M; Couturier J; Zucker JN; Henry I; Munnich A; Vekemans M; Lyonnet S
    Clin Genet; 1998 Apr; 53(4):278-80. PubMed ID: 9650765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A developmental context for multiple genetic alterations in Wilms' tumor.
    Feinberg AP
    J Cell Sci Suppl; 1994; 18():7-12. PubMed ID: 7883796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo.
    Liu K; He B; Xu J; Li Y; Guo C; Cai Q; Wang S
    Med Sci Monit; 2019 Feb; 25():1459-1468. PubMed ID: 30798328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
    Wang WH; Duan JX; Vu TH; Hoffman AR
    J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
    J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
    Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
    Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript.
    Algar EM; Kenney MT; Simms LA; Smith SI; Kida Y; Smith PJ
    Hum Mutat; 1995; 5(3):221-7. PubMed ID: 7599632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wilms' tumors and malformation complexes].
    Hata J; Fukuzawa R; Takata A; Kikuchi H
    Nihon Rinsho; 2000 Jul; 58(7):1419-25. PubMed ID: 10921316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney.
    Anglesio MS; Evdokimova V; Melnyk N; Zhang L; Fernandez CV; Grundy PE; Leach S; Marra MA; Brooks-Wilson AR; Penninger J; Sorensen PH
    Hum Mol Genet; 2004 Sep; 13(18):2061-74. PubMed ID: 15254018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.